Answers are grounded in this paper and cite their sources.
Introduction: Capecitabine ( CAP ) is an oral antineoplastic pro-drug, whose initial step of activation is carboxylesterase (CES) dependent. The main conversion of CAP to 5-DFCR occurs in the liver by CES1 and a minor part - in the gastrointestinal tract (GIT) by CES2. Usually, the enteral pro-drug activation is associated with the appearance of fluoropyrimidine GIT toxicity, which may be dose-limiting and life-threatening for the patient. Thus, it is important to clear out the factors that could influence on the activity of both CES isozymes. Aim: The aim of the present study was to present the mechanism of hydrolysis, sources of variability and modulation possibilities of CESs, that could affect the treatment with CAP . Materials and Methods: A systematic review of the scientific databases in PubMed, Science Direct and Google Scholar was conducted. Results: The literature data showed up to 89% inter-individual variability in the plasma content of CAP and its metabolites. It was also established that factors, such as genetic polymorphisms, age, gender, and diseases, are responsible for these variabilities. Enzyme inhibitors and inductors, on the other hand, are among the factors that could be controlled and used as reliable modulators for CAP therapy. In fact, some authors found that the inhibition of CAP hydrolysis at CES2 level could reduce the common GIT toxicity and improve the bioavailability of the pro-drug. Conclusion : In accordance with the individual patient, the CES activity modulation approach could be used for the enhancement of the CAP therapeutic index. However, further detailed in vivo researches are needed to achieve categorical and applicable results.
No takes yet. Share an insight, caveat, or question.
Stoeva et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: